Literature DB >> 22286395

Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy.

Véronique Bordas-Le Floch1, Laetitia Bussières, Sabi Airouche, Aurélie Lautrette, Julien Bouley, Nathalie Berjont, Stéphane Horiot, Axelle Huet, Karine Jain, Pierrick Lemoine, Henri Chabre, Thierry Batard, Laurent Mascarell, Véronique Baron-Bodo, Sophie Tourdot, Emmanuel Nony, Philippe Moingeon.   

Abstract

BACKGROUND: Recombinant allergens with a native conformation represent an alternative to natural extracts for immunotherapy and diagnostic purposes.
METHODS: We produced the Der p 2 mite allergen in Pichia pastoris and Escherichia coli. After purification by cation exchange chromatography, recombinant molecules were compared to their natural counterpart based upon structural (disulfide bonds, secondary structure, thermal stability) and immunological properties (antibody reactivity, basophil and T cell activation, tolerance induction in a murine sublingual immunotherapy model).
RESULTS: The Der p 2.0101 isoform was confirmed to be prevalent in Dermatophagoides pteronyssinus extracts. It was then produced as a secreted molecule in P. pastoris or refolded from E. coli inclusion bodies. The yeast-expressed rDer p 2 molecule exhibits a natural-like disulfide bridge distribution and secondary structure, whereas the E. coli-derived rDer p 2 presents some heterogeneity in cysteine bonds and a lower stability following thermal stress. The two recombinant as well as natural Der p 2 molecules exhibit comparable IgE recognition and activate basophil and CD4+ T cells. Sublingual immunotherapy of nDer p 2- sensitized mice using either one of the rDer p 2 molecules efficiently decreases airway hyperresponsiveness as well as Th2 responses.
CONCLUSIONS: Natural and recombinant Der p 2 molecules produced in P. pastoris and E. coli exhibit comparable immunological properties despite distinct structural features. Natural-like cysteine pairing is a critical parameter to identify stable, well-folded and homogenous proteins appropriate for immunotherapy and diagnostic purposes.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286395     DOI: 10.1159/000331143

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

Review 1.  Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Authors:  R Valenta; R Campana; K Marth; M van Hage
Journal:  J Intern Med       Date:  2012-08       Impact factor: 8.989

2.  Expression, cloning, and IgE-binding of the full-length dust mite allergen Der f 8.

Authors:  Yu-Bao Cui; Ying Zhou; Nan Wang; Fei-Xiang Teng; Li-Li Yu; Yong-Hua Bian; Jin-Xia Song; Li Yang; Cheng-Bo Zhang
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

3.  Design, production and immunomodulatory potency of a novel allergen bioparticle.

Authors:  Véronique Gomord; Virginie Stordeur; Anne-Catherine Fitchette; Elizabeth D Fixman; Guy Tropper; Lorna Garnier; Réjean Desgagnes; Sébastien Viel; Julie Couillard; Guillaume Beauverger; Sylvain Trepout; Brian J Ward; Ronald van Ree; Loic Faye; Louis-P Vézina
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

4.  Recombinant house dust mite allergens.

Authors:  Susanne Vrtala; Hans Huber; Wayne R Thomas
Journal:  Methods       Date:  2013-07-31       Impact factor: 3.608

5.  Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets.

Authors:  Margit Weghofer; Monika Grote; Yvonne Resch; Anne Casset; Michael Kneidinger; Jolanta Kopec; Wayne R Thomas; Enrique Fernández-Caldas; Michael Kabesch; Rosetta Ferrara; Adriano Mari; Ashok Purohit; Gabrielle Pauli; Friedrich Horak; Walter Keller; Peter Valent; Rudolf Valenta; Susanne Vrtala
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

6.  Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products.

Authors:  Catherine Thirion-Delalande; Frédéric Gervais; Cécile Fisch; Jean Cuiné; Véronique Baron-Bodo; Philippe Moingeon; Laurent Mascarell
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

Review 7.  Consideration of methods for identifying mite allergens.

Authors:  Yubao Cui; Qiong Wang; Haoyuan Jia
Journal:  Clin Transl Allergy       Date:  2018-04-27       Impact factor: 5.871

Review 8.  Safety of engineered allergen-specific immunotherapy vaccines.

Authors:  Margarete Focke-Tejkl; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.